High temperature cobalt-base alloy Patent

High temperature cobalt-base alloy resistant to corrosion by liquid metals and to sublimation in vacuum environmen

Cobalt-base alloy

A microstructurally stable, high strength cobalt based alloy for use at elevated temperatures to 2125 F was developed. The alloys are particularly directed for use in stators and other low stress components in advanced gas turbines

Advanced alloy design technique: High temperature cobalt base superalloy

Advanced alloy design technique was developed for treating alloys that will have extended life in service at high temperature and intermediate temperatures. Process stabilizes microstructure of the alloy by designing it so that compound identified with embrittlement is eliminated or minimized. Design process is being used to develop both nickel and cobalt-base superalloys

Effect of variations in silicon and iron content on embrittlement of L-605 /HS-25/

Silicon and iron content effects on ductility and tensile strength of cobalt alloy after agin

Nasa developments in cobalt-base superalloys

Chemical, mechanical and physical properties of cobalt-refractory-metal superalloys for high temperature aerospace application

Development of a cobalt-tungsten ferromagnetic, high-temperature, structural alloy

Cobalt-tungsten ferromagnetic, high temperature structural alloy for rotor applications in space power generator

Consolidated Edison Thorium Reactor-Reactor Vessel Internal Components Design

The design functions and fabrication details for internal components of the CETR are presented and pertinent analytical stress studies are summarized. Functions of the internal components include proper orientation and support for the fuel elements, proper distribution of primary coolant within the reactor vessel, and the establishment of guide channels for the control rods. (J.R.D.

Thermochemistry of Alane Complexes for Hydrogen Storage: A Theoretical and Experimental Comparison

Knowledge of the relative stabilities of alane (AlH3) complexes with electron donors is essential for identifying hydrogen storage materials for vehicular applications that can be regenerated by off-board methods; however, almost no thermodynamic data are available to make this assessment. To fill this gap, we employed the G4(MP2) method to determine heats of formation, entropies, and Gibbs free energies of formation for thirty-eight alane complexes with NH3-nRn (R = Me, Et; n = 0-3), pyridine, pyrazine, triethylenediamine (TEDA), quinuclidine, OH2-nRn (R = Me, Et; n = 0-2), dioxane, and tetrahydrofuran (THF). Monomer, bis, and selected dimer complex geometries were considered. Using these data, we computed the thermodynamics of the key formation and dehydrogenation reactions that would occur during hydrogen delivery and alane regeneration, from which trends in complex stability were identified. These predictions were tested by synthesizing six amine-alane complexes involving trimethylamine, triethylamine, dimethylethylamine, TEDA, quinuclidine, and hexamine, and obtaining upper limits of delta G for their formation from metallic aluminum. Combining these computational and experimental results, we establish a criterion for complex stability relevant to hydrogen storage that can be used to assess potential ligands prior to attempting synthesis of the alane complex. Based on this, we conclude that only a subset of the tertiary amine complexes considered and none of the ether complexes can be successfully formed by direct reaction with aluminum and regenerated in an alane-based hydrogen storage system.Comment: Accepted by the Journal of Physical Chemistry

Benefits of early treatment with natalizumab: A real-world study

BACKGROUND: The impact of early versus later high-efficacy disease-modifying therapy (DMT) in patients with multiple sclerosis (MS) is uncertain. This study reported the association of early versus later natalizumab treatment with real-world clinical outcomes in MS patients. METHODS: The study included 661 participants diagnosed with MS in 1994 or later from 7 US centers participating in the MS Partners Advancing Technology for Health Solutions (MS PATHS) network. Time to natalizumab treatment between diagnosis and first infusion (TTNT) was determined from the Tysabri Outreach: Unified Commitment to Health (TOUCH) registry. Clinical outcomes were defined using neuroperformance tests included in the Multiple Sclerosis Performance Test. Associations were tested using TTNT as a categorical and continuous variable. Linear mixed models addressed within-subject and within-site clustering. RESULTS: TTNT varied from 0.1 to 19.8 years (median [interquartile range] 4.2 [1.8, 9.0] years). A significant association between later natalizumab use and worse outcomes was demonstrated for walking speed (p \u3c 0.001), processing speed (p \u3c 0.001), manual dexterity (p \u3c 0.001), brain atrophy (p = 0.001), and T2 lesion volume (p = 0.02). Covariate-adjusted modelling of a sensitivity population diagnosed with MS in 2006 or later (n = 424) demonstrated significant associations between longer TTNT and worse walking speed (p \u3c 0.05), processing speed (p \u3c 0.001), and manual dexterity (p \u3c 0.001). CONCLUSION: Later initiation of natalizumab was associated with worse clinical and radiologic imaging outcomes. Thus, high-efficacy DMT may have greater benefit when started earlier in MS patients. These results provide a rationale for randomized controlled trials to further assess the impact of early highly-effective DMT use versus later escalation of therapy